BACKGROUND: In the post-pandemic period, pandemic (H1N1) 2009 virus was expected to circulate seasonally and was introduced into trivalent influenza vaccine during 2010/2011 season in the Northern Hemisphere. OBJECTIVES: The aim of this study was to examine the evolution of herd immunity against pandemic (H1N1) 2009 virus in Beijing, China, during 2010/2011 season and effectiveness of the 2010/2011 trivalent vaccine. METHODS: Two serological surveys were conducted before and after 2010/2011 season in Beijing. A case-control study was used to investigate vaccine effectiveness against influenza-like illness (ILI) and lower respiratory tract infection (LRI). RESULTS: A total of 4509 and 4543 subjects participated in the pre- and post-season surveys, respectively. The standardized seroprevalence of pandemic (H1N1) 2009 influenza increased from 22.1% pre-season to 24.3% post-season (P<0.001). Significant elevation in seroprevalence appeared in the ≥ 60 years age-group (P<0.001), but not in others. The 2010/2011 trivalent vaccine contributed to the higher post-seasonal seroprevalence in unvaccinated individuals (P=0.024), but not in those vaccinated with monovalent pandemic vaccine (P=0.205), as well as in those without prior immunity versus those with immunity. The adjusted effectiveness of the 2010/2011 trivalent vaccine was 79% protection against ILI (95% CI, 61-89%) and 95% against LRI (95% CI: 59-99%). CONCLUSIONS: A slight increase in herd immunity against pandemic (H1N1) 2009 influenza was observed in Beijing, China, during the 2010/2011 season. Prior vaccination and immunity had a suppressive impact on immune response toward this novel influenza virus, elicited by 2010/2011 trivalent vaccine. This trivalent vaccine conferred good protection against ILI and LRI.
BACKGROUND: In the post-pandemic period, pandemic (H1N1) 2009 virus was expected to circulate seasonally and was introduced into trivalent influenza vaccine during 2010/2011 season in the Northern Hemisphere. OBJECTIVES: The aim of this study was to examine the evolution of herd immunity against pandemic (H1N1) 2009 virus in Beijing, China, during 2010/2011 season and effectiveness of the 2010/2011 trivalent vaccine. METHODS: Two serological surveys were conducted before and after 2010/2011 season in Beijing. A case-control study was used to investigate vaccine effectiveness against influenza-like illness (ILI) and lower respiratory tract infection (LRI). RESULTS: A total of 4509 and 4543 subjects participated in the pre- and post-season surveys, respectively. The standardized seroprevalence of pandemic (H1N1) 2009 influenza increased from 22.1% pre-season to 24.3% post-season (P<0.001). Significant elevation in seroprevalence appeared in the ≥ 60 years age-group (P<0.001), but not in others. The 2010/2011 trivalent vaccine contributed to the higher post-seasonal seroprevalence in unvaccinated individuals (P=0.024), but not in those vaccinated with monovalent pandemic vaccine (P=0.205), as well as in those without prior immunity versus those with immunity. The adjusted effectiveness of the 2010/2011 trivalent vaccine was 79% protection against ILI (95% CI, 61-89%) and 95% against LRI (95% CI: 59-99%). CONCLUSIONS: A slight increase in herd immunity against pandemic (H1N1) 2009 influenza was observed in Beijing, China, during the 2010/2011 season. Prior vaccination and immunity had a suppressive impact on immune response toward this novel influenza virus, elicited by 2010/2011 trivalent vaccine. This trivalent vaccine conferred good protection against ILI and LRI.
Authors: Donna M Murasko; Erica D Bernstein; Elizabeth M Gardner; Peter Gross; Gary Munk; Sandra Dran; Elias Abrutyn Journal: Exp Gerontol Date: 2002 Jan-Mar Impact factor: 4.032
Authors: Vernon J Lee; Jonathan Yap; Alex R Cook; Mark I Chen; Joshua K Tay; Ian Barr; Anne Kelso; Boon Huan Tan; Jin Phang Loh; Raymond Lin; Lin Cui; Paul M Kelly; Yee Sin Leo; Kee Seng Chia; Wee Lee Kang; Paul A Tambyah; Benjamin Seet Journal: J Infect Dis Date: 2010-11-01 Impact factor: 5.226
Authors: Terry Guthrie; Christopher G L Hobbs; Victoria Davenport; Rachel E Horton; Robert S Heyderman; Neil A Williams Journal: J Infect Dis Date: 2004-10-27 Impact factor: 5.226
Authors: Mary Dawn T Co; Laura Orphin; John Cruz; Pamela Pazoles; Alan L Rothman; Francis A Ennis; Masanori Terajima Journal: Vaccine Date: 2008-02-26 Impact factor: 3.641
Authors: J Castilla; J Moran; V Martinez-Artola; G Reina; I Martinez-Baz; M Garcia Cenoz; N Alvarez; F Irisarri; M Arriazu; F Elia; E Salcedo Journal: Euro Surveill Date: 2011-02-17
Authors: Mark I C Chen; Vernon J M Lee; Wei-Yen Lim; Ian G Barr; Raymond T P Lin; Gerald C H Koh; Jonathan Yap; Lin Cui; Alex R Cook; Karen Laurie; Linda W L Tan; Boon Huan Tan; Jimmy Loh; Robert Shaw; Chris Durrant; Vincent T K Chow; Anne Kelso; Kee Seng Chia; Yee Sin Leo Journal: JAMA Date: 2010-04-14 Impact factor: 56.272
Authors: Seema Jain; Laurie Kamimoto; Anna M Bramley; Ann M Schmitz; Stephen R Benoit; Janice Louie; David E Sugerman; Jean K Druckenmiller; Kathleen A Ritger; Rashmi Chugh; Supriya Jasuja; Meredith Deutscher; Sanny Chen; John D Walker; Jeffrey S Duchin; Susan Lett; Susan Soliva; Eden V Wells; David Swerdlow; Timothy M Uyeki; Anthony E Fiore; Sonja J Olsen; Alicia M Fry; Carolyn B Bridges; Lyn Finelli Journal: N Engl J Med Date: 2009-10-08 Impact factor: 91.245
Authors: Won Suk Choi; Ji Yun Noh; Yu Bin Seo; Ji Hyeon Baek; Jacob Lee; Joon Young Song; Dae Won Park; Jin Soo Lee; Hee Jin Cheong; Woo Joo Kim Journal: Clin Vaccine Immunol Date: 2013-04-10
Authors: Jodie McVernon; Karen Laurie; Helen Faddy; David Irving; Terry Nolan; Ian Barr; Anne Kelso Journal: Influenza Other Respir Viruses Date: 2013-12-31 Impact factor: 4.380
Authors: Hillary A Vanderven; Fernanda Ana-Sosa-Batiz; Sinthujan Jegaskanda; Steven Rockman; Karen Laurie; Ian Barr; Weisan Chen; Bruce Wines; P Mark Hogarth; Teresa Lambe; Sarah C Gilbert; Matthew S Parsons; Stephen J Kent Journal: EBioMedicine Date: 2016-04-28 Impact factor: 8.143